Complement Receptor 1: disease associations and therapeutic implications

Mol Immunol. 2009 Feb;46(5):761-72. doi: 10.1016/j.molimm.2008.09.026. Epub 2008 Nov 11.

Abstract

Exaggerated complement activation is a key event in the pathogenesis of a range of autoimmune and inflammatory diseases. Complement Receptor 1 (CR1) has emerged as a molecule of immense interest in gaining insight to the susceptibility, pathophysiology, diagnosis, prognosis and therapy of such diseases. This review brings forth a composite view of the current understanding on the structure, functions, genetics, disease associations and therapeutic implications of CR1.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Autoimmune Diseases / genetics
  • Autoimmune Diseases / immunology*
  • Autoimmune Diseases / therapy
  • Humans
  • Inflammation / genetics
  • Inflammation / immunology
  • Inflammation / therapy
  • Receptors, Complement 3b / genetics
  • Receptors, Complement 3b / immunology*

Substances

  • CR1 protein, human
  • Receptors, Complement 3b